San Francisco, April 22, 2016 (GLOBE NEWSWIRE) -- Functional (non ulcer) dyspepsia is a condition characterized by symptoms of indigestion, without any obvious cause. It causes signs that resemble those of an ulcer e.g. pain and discomfort in upper abdomen, bloating, nausea, belching, etc. Functional (non ulcer) dyspepsia is chronic in nature. It is called functional as measurable or observable structural abnormalities are absent, however the symptoms are persistent. Alternative terms for the disorder include gastritis, nervous dyspepsia, pseudo-ulcer syndrome, and pyloro-duodenal irritability.
Browse Full Research Report With TOC On "Global 2-Ethylhexanoic Acid Market Research Report 2015" at: http://www.radiantinsights.com/research/global-2-ethylhexanoic-acid-market-research-report-2015
Common triggers of functional (non ulcer) dyspepsia are improper lifestyle and diet, medications, inflammation of duodenum or stomach, and excessive acid secretion. It is also triggered by food allergies and Helicobacter Pylori infection. Management of the condition calls for limiting or avoiding fatty or fried foods, excessive alcohol, caffeine, and tomatoes, among other. Having smaller, more frequent meals also has a favorable effect. Reduction in the overall stress level helps to lowers symptoms.
Key factors in the therapeutic development for functional (non ulcer) dyspepsia involve RoA – Route of Administration, MoA – Mechanism of Action, molecule type, and drug target. Medications encompass low-dose antidepressants, over-the-counter gas remedies, H2-receptor blockers, proton pump inhibitors, etc.
See More Reports of This Category by Radiant Insights: www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
While H-2 receptor blockers reduce acid production, proton pump inhibitors shut down acid ‘pumps’ in the stomach cells. Antibiotics are prescribed if the presence of H. pylori bacterium is detected. Prokinetic agents strengthen the esophageal sphincter and help the stomach empty faster. This reduces upper abdominal discomfort. However these drugs may not work for all. Moreover they are associated with significant side-effects.
Eminent participants in the market for treatment of functional (non ulcer) dyspepsia are Almirall S.A., Ironwood Pharmaceuticals Inc., Eisai Co. Ltd., Zeria Pharmaceutical Co. Ltd., RaQualia Pharmaceuticals Inc., and Rottapharm SpA. Leading drugs include 5-BOIP, acotiamide hydrochloride, cinitapride, and dexloxiglumide. Drugs in the research and development phase are IW-9179, RQ-00000010, RQ-00201894, rabeprazole sodium, etc.
Request A Sample Copy Of This Report at: www.radiantinsights.com/research/functional-non-ulcer-dyspepsia-pipeline-review-h1-2015#tabs-4
RaQualia, in 2012, got approval for conducting a First-In-Human study of RQ-00000010. Ministry of Health in Japan approved the marketing of Acofide developed by Zeria Pharmaceuticals, for treating functional (non ulcer) dyspepsia, in 2013. On the other hand, Ironwood recently announced that it has abandoned the Phase IIa Study of IW-9179 as data was non-indicative of reduction in symptoms.
Explore Other Reports By Radiant Insights,Inc at
- Over-the-top communications services Market –
- SDN/NFV technologies –
About Radiant Insights
Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy.Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake.
Corporate Sales Specialist, USA
Radiant Insights, Inc
Toll Free: 1-888-202-9519
Source: Radiant Insights